Publications by authors named "E Van Gorp"
Introduction: Severe COVID-19 is associated with reduced absolute lymphocyte counts, suggesting that lymphocyte subsets may serve as predictors of clinical outcomes in affected patients. Early identification of patients at risk for severe disease is crucial for optimizing care, accurately informing patients and their families, guiding therapeutic interventions, and improving patient flow in the ED. Given that immunosuppressive drugs significantly impact lymphocyte profiles, we aimed to determine the association between prior use of immunosuppressive drugs, lymphocyte subsets, and COVID-19 severity in our population with a high prevalence of immunosuppression.
View Article and Find Full Text PDFIntroduction: The goal of this study is to validate the accuracy of the 29-mRNA host response classifiers Inflammatix Bacterial-Viral-Non infected-3b (IMX-BVN-3b) and Severity-3b (IMX-SEV-3b) to identify bacterial and viral infections and to predict 30-day mortality in patients with suspected infections in the ED.
Methods: This prospective observational cohort study enrolled patients with suspected infections in a tertiary ED. IMX-BVN-3b was compared to clinically forced and consensus adjudicated bacterial/viral infection status and IMX-SEV-3b was compared to 30-day mortality.
Article Synopsis
- Catheter-associated urinary tract infections (CA-UTIs) are common hospital infections; this study evaluates the effectiveness of ciprofloxacin against these infections using an in vitro model.
- Researchers tested three standard bacterial strains and 45 clinical isolates to measure biofilm mass and bacterial density before and after treatment with ciprofloxacin.
- Results showed that while K. pneumoniae biofilms were more resistant to disruption, E. coli showed persistent growth in the bladder, and Pseudomonas aeruginosa had higher rates of ciprofloxacin resistance.
The role of antibody-dependent enhancement in dengue vaccination.
Trop Dis Travel Med Vaccines
November 2024
Dengue is the most rapidly spreading vector-borne disease worldwide, with over half the global population at risk for an infection. Antibody-dependent enhancement (ADE) is associated with increased disease severity and may also be attributable to the deterioration of disease in vaccinated people. Two dengue vaccines are approved momentarily, with more in development.
View Article and Find Full Text PDFArticle Synopsis
- MERS-CoV is a serious respiratory virus with a high mortality rate and currently no licensed vaccines, prompting research into a candidate vaccine called MVA-MERS-S, which uses a modified vaccinia virus.
- A phase 1b clinical trial was conducted with healthy volunteers (ages 18-55) across Germany and the Netherlands to evaluate the safety and immunogenicity of MVA-MERS-S, testing various dosing schedules and comparing it to a placebo group.
- The trial involved 244 screened participants, with 140 randomly assigned to different dosing regimens, and the outcomes focused on both the safety of the vaccine and the resulting immune response measured through antibody levels and seroconversion rates.